Skip to main content
Journal cover image

Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients

Publication ,  Journal Article
Morse, M; Gabitzsch, E; Balint, JP; Xu, Y; Lyerly, HK; Jones, F
Published in: Journal for immunotherapy of cancer
January 2013

Duke Scholars

Published In

Journal for immunotherapy of cancer

DOI

EISSN

2051-1426

ISSN

2051-1426

Publication Date

January 2013

Volume

1

Issue

Suppl 1

Start / End Page

P129 / P129

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Morse, M., Gabitzsch, E., Balint, J. P., Xu, Y., Lyerly, H. K., & Jones, F. (2013). Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Journal for Immunotherapy of Cancer, 1(Suppl 1), P129–P129. https://doi.org/10.1186/2051-1426-1-s1-p129
Morse, Michael, Elizabeth Gabitzsch, Joseph P. Balint, Younong Xu, H. K. Lyerly, and Frank Jones. “Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.” Journal for Immunotherapy of Cancer 1, no. Suppl 1 (January 2013): P129–P129. https://doi.org/10.1186/2051-1426-1-s1-p129.
Morse M, Gabitzsch E, Balint JP, Xu Y, Lyerly HK, Jones F. Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Journal for immunotherapy of cancer. 2013 Jan;1(Suppl 1):P129–P129.
Morse, Michael, et al. “Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.” Journal for Immunotherapy of Cancer, vol. 1, no. Suppl 1, Jan. 2013, pp. P129–P129. Epmc, doi:10.1186/2051-1426-1-s1-p129.
Morse M, Gabitzsch E, Balint JP, Xu Y, Lyerly HK, Jones F. Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Journal for immunotherapy of cancer. 2013 Jan;1(Suppl 1):P129–P129.
Journal cover image

Published In

Journal for immunotherapy of cancer

DOI

EISSN

2051-1426

ISSN

2051-1426

Publication Date

January 2013

Volume

1

Issue

Suppl 1

Start / End Page

P129 / P129

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology